Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Epicenter who wrote (1727)	2/11/1999 9:27:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 10280

The ML brief report on the conference mentions 13 new drugs by 2002. Initially, I could only come up with 12 candidates: We have 5 partnered drugs (Allegra, Claritin, Hismanal, Propulsid, Prozac). Then I would assume Xopenex, formoterol, cetirizine, oxybutinin, sibutramine, ketoprofen and doxazosin (Cardura). I found the missing one on the slides at the SEPR web site (under presentations). It's an ICE for Effexor, a major anti-depressant. Don't recall seeing this discussed before (although it's getting hard for us biotech-types used to 1- or 2-drug companies to keep track of all these drugs <G>), and it's on a very aggressive time-line. BTW, the slides say 13 NDA's by 2002, which seems a little more realistic but still very aggressive. The Claritin II NDA for this year is very good news indeed. SGP must really be hustling. Peter